secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001104659-23-119726
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's
--------------------------------------------------------------------------------

- First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.
- Up to 5 cohorts of 8 healthy volunteers each receive a single ascending dose; 85-day study with optional Day 120 follow-up.
- Initial safety and pharmacokinetic data expected in first half of 2024.
- Company raised >$20M in Q3 2023 private placement to support development through clinical milestones.
- CEO Gail Farfel highlights transition to clinical stage and potential differentiation from other AD treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/0001104659-23-119726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/tm2331130d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-119726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer